Company intelligence / Profile preview

Alpha Fusion, Inc.

Osaka, Osaka Prefecture, Japanalpha-fusion.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Alpha Fusion is advancing its pipeline and has made significant progress since Series A funding in May 2023, including development of its first pipeline for Thyroid Cancer. The company is preparing for company-sponsored clinical trials and GMP-grade Astatine drug production.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalsTargeted Alpha Therapy (TAT)Astatine (At-211) based therapeutics
Industry: Biotech

Drug pipeline

3 assets

[211At]PSMA-5

2 more assets in the full pipeline.

Request access →

Partnerships

Osaka UniversityJapan Science and Technology Agency (JST)collaboration with cyclotrons for supply chain

Beyond the preview

Go deeper on Alpha Fusion, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha Fusion, Inc..

Explore the full profile